サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1672117

子宮頸がん治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2025年から2033年までの予測

Global Cervical Cancer Treatment Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

出版日
ページ情報
英文 145 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
子宮頸がん治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2025年から2033年までの予測
出版日: 2025年03月01日
発行: Value Market Research
ページ情報: 英文 145 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

子宮頸がん治療の世界市場規模は、2024年の91億米ドルから2033年には153億9,000万米ドルに成長し、2026年から2033年の予測期間中に6.02％の堅調な年間平均成長率（CAGR）を示すと予測されます。

子宮頸がん治療市場は、子宮頸がんの罹患率の増加、予防対策や治療オプションに対する意識の高まりに牽引され、大きな成長が見込まれています。子宮頸がんは、主にヒトパピローマウイルス（HPV）感染によって引き起こされ、世界中の女性に重大な健康リスクをもたらしています。ヘルスケアプロバイダーや医療機関が早期発見と効果的な治療を優先する中、手術、放射線療法、化学療法を含む子宮頸がん治療に対する需要は増加すると予想され、同市場は堅調な拡大が見込まれています。

さらに、子宮頸がん治療技術の進歩が市場内の技術革新を促進しています。標的治療薬や免疫療法の開発は治療状況に革命をもたらし、進行・再発子宮頸がん患者に新たな選択肢を提供しています。これらの革新的なアプローチは、治療効果を向上させるだけでなく、副作用を最小限に抑え、患者の全体的なQOLを向上させる。新たな治療法や併用療法の研究が進むにつれて、子宮頸がん治療市場は、患者の予後改善が期待されることから、さらに拡大する可能性が高いです。

さらに、予防医療とワクチン接種が重視されるようになり、子宮頸がん治療の展望が形成されつつあります。HPVワクチンのイントロダクションは、ワクチン接種集団における子宮頸がんの発生率を大幅に低下させ、予防対策の重要性を浮き彫りにしています。ワクチン接種と定期的な検診の利点に対する認識が高まるにつれて、子宮頸がん治療に対する需要は、予防と疾患の効果的な管理の両方に焦点を当てながら進化していくと予想されます。子宮頸がん治療市場が成長を続ける中、革新的な治療法、予防戦略、患者ケアの改善への取り組みの組み合わせが、将来の軌道を形成する上で重要な役割を果たすでしょう。

当社のレポートは、様々な産業や市場に関する包括的かつ実用的な洞察をお客様に提供するために綿密に作成されています。各レポートは、市場情勢を完全に理解するために、いくつかの重要な要素を含んでいます：

市場概要：市場概要：定義、分類、業界の現状など、市場に関する詳細なイントロダクション

市場促進要因：市場成長に影響を与える主な促進要因・抑制要因・市場促進要因・課題を詳細に分析します。このセクションでは、技術の進歩、規制の変更、新たな動向などの要因を検証します。

セグメンテーション分析：製品タイプ、用途、最終用途、地域などの基準に基づき、市場を明確なセグメントに内訳。この分析により、各セグメントの業績と将来性を明らかにします。

競合情勢：市場シェア、製品ポートフォリオ、戦略的イニシアティブ、財務実績など、主要市場プレイヤーの包括的評価。主要企業が採用する競合力学と主要戦略に関する考察を提供します。

市場予測：過去のデータと現在の市場状況に基づき、一定期間における市場規模と成長動向を予測します。これには、定量的分析と将来の市場軌跡を示すグラフ表示が含まれます。

地域分析：地域ごとの市場パフォーマンスを評価し、主要市場や地域動向を明らかにします。地域の市場力学とビジネスチャンスを理解するのに役立ちます。

新たな動向と機会：現在の市場動向と新たな市場動向、技術革新、潜在的な投資対象分野を特定します。将来の市場開拓と成長見通しに関する洞察を提供します。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 子宮頸がん治療産業分析

  • イントロダクション-市場力学
  • 市場促進要因
  • 市場抑制要因
  • 機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 子宮頸がん治療の世界市場分析：タイプ別

  • タイプ別、概要
  • タイプ別、過去および予測データ分析
  • 扁平上皮がん
  • 腺がん
  • 腺扁平上皮がん
  • その他のタイプ

第6章 子宮頸がん治療の世界市場分析：治療別

  • 治療別、概要
  • 治療別、過去および予測データ分析
  • 放射線療法
  • 化学療法
  • 標的療法
  • 免疫療法
  • その他の治療法

第7章 子宮頸がん治療の世界市場分析：最終用途別

  • 最終用途別、概要
  • 最終用途別、過去および予測データ分析
  • 病院およびクリニック
  • 外来手術センター
  • その他

第8章 子宮頸がん治療の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋地域売上分析
    • 概要、実績と予測
    • アジア太平洋地域：セグメント別
    • アジア太平洋地域国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋地域
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ国別一覧
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ

第9章 子宮頸がん治療企業の競合情勢

  • 子宮頸がん治療市場の競合
  • 提携/協力/合意
  • 合併・買収
  • 新製品の発売
  • その他の開発

第10章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Merck & Co. Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Eli Lilly And Company.
  • Novartis AG
  • AstraZeneca
  • GSK Plc.
  • AbbVie Inc.
  • Johnson & Johnson Services Inc
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Type (USD MN)
  • Squamous Cell Carcinoma Market Sales By Geography (USD MN)
  • Adenocarcinoma Market Sales By Geography (USD MN)
  • Adenosquamous Carcinoma Market Sales By Geography (USD MN)
  • Other Types Market Sales By Geography (USD MN)
  • Analysis By Treatment (USD MN)
  • Radiation Therapy Market Sales By Geography (USD MN)
  • Chemotherapy Market Sales By Geography (USD MN)
  • Targeted Therapy Market Sales By Geography (USD MN)
  • Immunotherapy Market Sales By Geography (USD MN)
  • Other Therapies Market Sales By Geography (USD MN)
  • Analysis By End-use (USD MN)
  • Hospitals & Clinics Market Sales By Geography (USD MN)
  • Ambulatory Surgery Centers Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Cervical Cancer Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Cervical Cancer Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Cervical Cancer Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Type
  • Market Attractiveness Analysis By Treatment
  • Market Attractiveness Analysis By End-use
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Type (USD MN)
  • Squamous Cell Carcinoma Market Sales By Geography (USD MN)
  • Adenocarcinoma Market Sales By Geography (USD MN)
  • Adenosquamous Carcinoma Market Sales By Geography (USD MN)
  • Other Types Market Sales By Geography (USD MN)
  • Global Market Analysis By Treatment (USD MN)
  • Radiation Therapy Market Sales By Geography (USD MN)
  • Chemotherapy Market Sales By Geography (USD MN)
  • Targeted Therapy Market Sales By Geography (USD MN)
  • Immunotherapy Market Sales By Geography (USD MN)
  • Other Therapies Market Sales By Geography (USD MN)
  • Global Market Analysis By End-use (USD MN)
  • Hospitals & Clinics Market Sales By Geography (USD MN)
  • Ambulatory Surgery Centers Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis
  • Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
目次
Product Code: VMR11210754

Global Cervical Cancer Treatment Market size is anticipated to grow from USD 9.1 Billion in 2024 to USD 15.39 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 6.02% during the forecast period of 2026 to 2033.

The cervical cancer treatment market is poised for significant growth, driven by the increasing incidence of cervical cancer and the rising awareness of preventive measures and treatment options. Cervical cancer, primarily caused by human papillomavirus (HPV) infection, poses a significant health risk to women worldwide. As healthcare providers and organizations prioritize early detection and effective treatment, the demand for cervical cancer therapies, including surgery, radiation therapy, and chemotherapy, is expected to rise, positioning this market for robust expansion.

Moreover, advancements in cervical cancer treatment technologies are driving innovation within the market. The development of targeted therapies and immunotherapies is revolutionizing the treatment landscape, offering new options for patients with advanced or recurrent cervical cancer. These innovative approaches not only improve treatment efficacy but also minimize side effects, enhancing the overall quality of life for patients. As research continues to explore new therapeutic modalities and combination treatments, the cervical cancer treatment market is likely to expand further, driven by the promise of improved patient outcomes.

Additionally, the growing emphasis on preventive care and vaccination is shaping the cervical cancer treatment landscape. The introduction of HPV vaccines has significantly reduced the incidence of cervical cancer in vaccinated populations, highlighting the importance of preventive measures. As awareness of the benefits of vaccination and regular screenings increases, the demand for cervical cancer treatments is expected to evolve, focusing on both prevention and effective management of the disease. As the cervical cancer treatment market continues to grow, the combination of innovative therapies, preventive strategies, and a commitment to improving patient care will play a crucial role in shaping its future trajectory.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Type

  • Squamous Cell Carcinoma
  • Adenocarcinoma
  • Adenosquamous Carcinoma
  • Other Types

By Treatment

  • Radiation Therapy
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Other Therapies

By End-use

  • Hospitals & Clinics
  • Ambulatory Surgery Centers
  • Others
  • COMPANIES PROFILED
  • Merck & Co. Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Eli Lilly and Company.
  • Novartis AG
  • AstraZeneca
  • GSK plc.
  • AbbVie Inc.
  • Johnson & Johnson Services Inc.
  • The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. CERVICAL CANCER TREATMENT INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porters Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Type
    • 3.7.2 Market Attractiveness Analysis By Treatment
    • 3.7.3 Market Attractiveness Analysis By End-use
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CERVICAL CANCER TREATMENT MARKET ANALYSIS BY TYPE

  • 5.1. Overview By Type
  • 5.2. Historical and Forecast Data Analysis By Type
  • 5.3. Squamous Cell Carcinoma Historic and Forecast Sales By Regions
  • 5.4. Adenocarcinoma Historic and Forecast Sales By Regions
  • 5.5. Adenosquamous Carcinoma Historic and Forecast Sales By Regions
  • 5.6. Other Types Historic and Forecast Sales By Regions

6. GLOBAL CERVICAL CANCER TREATMENT MARKET ANALYSIS BY TREATMENT

  • 6.1. Overview By Treatment
  • 6.2. Historical and Forecast Data Analysis By Treatment
  • 6.3. Radiation Therapy Historic and Forecast Sales By Regions
  • 6.4. Chemotherapy Historic and Forecast Sales By Regions
  • 6.5. Targeted Therapy Historic and Forecast Sales By Regions
  • 6.6. Immunotherapy Historic and Forecast Sales By Regions
  • 6.7. Other Therapies Historic and Forecast Sales By Regions

7. GLOBAL CERVICAL CANCER TREATMENT MARKET ANALYSIS BY END-USE

  • 7.1. Overview By End-use
  • 7.2. Historical and Forecast Data Analysis By End-use
  • 7.3. Hospitals & Clinics Historic and Forecast Sales By Regions
  • 7.4. Ambulatory Surgery Centers Historic and Forecast Sales By Regions
  • 7.5. Others Historic and Forecast Sales By Regions

8. GLOBAL CERVICAL CANCER TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE CERVICAL CANCER TREATMENT COMPANIES

  • 9.1. Cervical Cancer Treatment Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF CERVICAL CANCER TREATMENT INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Merck & Co. Inc.
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. Bristol-Myers Squibb Company
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. F. Hoffmann-La Roche Ltd
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. Pfizer Inc.
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. Eli Lilly And Company.
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. Novartis AG
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. AstraZeneca
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. GSK Plc.
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments
  • 10.11. AbbVie Inc.
    • 10.11.1 Company Overview
    • 10.11.2 Company Revenue
    • 10.11.3 Products
    • 10.11.4 Recent Developments
  • 10.12. Johnson & Johnson Services Inc
    • 10.12.1 Company Overview
    • 10.12.2 Company Revenue
    • 10.12.3 Products
    • 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies